Global Medical REIT Inc. — FY2023 Form 10-K
Issuer identification: The filing names Global Medical REIT Inc. (NYSE: GMRE; preferred stock: GMRE PrA), not Chiron Real Estate Inc. The issuer in the request metadata and the filing do not match; verify the intended company. Fiscal year ended December 31, 2023; amounts below are U.S. dollars.
Business context
GMRE is an internally managed healthcare REIT that owns and leases medical office buildings and other healthcare facilities, primarily under medium- to long-term leases. At year-end, it reported 185 buildings, approximately 4.75 million leasable square feet and $110.2 million of annualized base rent. Approximately 3.5% of leasable space was vacant.
Financial and operating metrics
| Metric | FY2023 / year-end | FY2022 / comparison |
|---|---|---|
| Total revenue | $141.0 million | $137.3 million |
| Net income | $21.7 million | $20.0 million |
| Net income attributable to common stockholders | $14.8 million; reported EPS $0.23 | $13.3 million; EPS $0.20 |
| Income before property-sale gains and debt-extinguishment loss | $7.0 million | $13.2 million |
| FFO / AFFO per share and unit | $0.83 / $0.91 | $0.92 / $0.98 |
| Cash from operating activities | $68.4 million | $76.5 million |
| Debt, net | $611.2 million | $694.1 million |
| Cash and restricted cash | $6.7 million | $14.5 million |
| Total assets / total equity | $1.268 billion / $605.8 million | $1.393 billion / $649.1 million |
Interest expense rose to $30.9 million from $25.2 million; the weighted-average debt rate for the year increased to 4.12% from 3.43%. Year-end weighted-average debt rate was 3.83%, reflecting interest-rate swaps. The $400 million revolver had $92.4 million drawn at year-end; unused Credit Facility capacity was reported as $293.6 million at February 26, 2024. The filing cites approximately $34.8 million of 2024 principal and interest payments and $655.5 million thereafter.
Common dividends were $0.21 per share quarterly, or $0.84 for the year, unchanged from 2022. Series A preferred stock dividends were $5.8 million; its 7.50% annual dividend is cumulative. The board retains discretion over future distributions.
Changes versus FY2022
- Revenue increased 2.7%, largely due to a full year of rent from 2022 acquisitions; tenant reserves and property sales partly offset the increase.
- Net income increased, but income before sale gains and debt-extinguishment loss declined. Higher interest expense and operating expenses weighed on results; property-sale gains increased to $15.6 million from $6.8 million.
- Acquisition activity fell sharply: one acquisition for $6.7 million in 2023 versus 14 acquisitions totaling $148.9 million in 2022. Three dispositions generated $80.5 million of gross proceeds and $15.6 million of gains.
- FFO and AFFO per share and unit declined. Operating cash flow fell by $8.1 million.
- Net debt declined by $82.9 million. The company defeased a CMBS loan in December for a total payment of $31.5 million, recording a $0.9 million loss; $8.4 million of escrowed funds was subsequently returned and applied to debt reduction.
Outlook, risks and unusual items
No quantified earnings or acquisition guidance is provided. Management identifies aging demographics, outpatient-care growth and provider consolidation as potential tailwinds. It cautions that high interest rates and a low share price raise the cost of capital and constrain acquisitions; management also expected rates to remain elevated at least into the first half of 2024, while noting rate forecasts were uncertain.
- Key exposures include tenant rent-paying ability, reimbursement and healthcare regulation, labor costs, lease renewals, and single-tenant properties. The three largest tenants represented 18.7% of annualized base rent; LifePoint and Encompass each represented about 7%.
- Geographic concentration includes Texas (18.7% of annualized base rent), Florida (10.6%) and Ohio (8.6%). Leases representing 12.8% of annualized base rent expire in 2024.
- Floating-rate revolver borrowings were unhedged. At year-end, a 100-basis-point SOFR increase was estimated to reduce annual cash flow by about $0.9 million, assuming no change in variable-rate debt. Swaps cover the term loans, not the revolver.
- Capital improvement commitments were approximately $18 million, with about $14 million expected in the next 12 months. Preferred stock redemption, if elected, would require $77.6 million plus accrued dividends, fees and expenses.
- The company reported no material pending litigation or known material environmental liability, and no real estate impairment loss for 2023. The auditor gave unqualified opinions on the financial statements and internal controls.
Most important facts to verify
- Confirm the intended issuer: the supplied filing is for Global Medical REIT Inc., not Chiron Real Estate Inc.
- Reconcile reported EPS: the statements and MD&A report $0.23, while an FFO reconciliation table reports $0.24 for 2023 net income attributable to common stockholders per share.
- Review debt maturities, covenant headroom, available revolver capacity and the refinancing plan, especially the Dumfries loan maturing in June 2024 and Credit Facility maturities beginning in 2026.
- Assess tenant credit and renewal exposure, including 2024 lease expirations and the concentration in major tenants and states.
- Evaluate dividend coverage against AFFO, operating cash flow, capital needs and cumulative preferred dividends; FFO and AFFO are non-GAAP measures.